Critical Contrast: NewGenIvf Group (NASDAQ:NIVF) & Mangoceuticals (NASDAQ:MGRX)

Institutional and Insider Ownership

66.2% of NewGenIvf Group shares are held by institutional investors. Comparatively, 56.7% of Mangoceuticals shares are held by institutional investors. 31.8% of NewGenIvf Group shares are held by insiders. Comparatively, 39.3% of Mangoceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares NewGenIvf Group and Mangoceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewGenIvf Group	$5.14 million	0.51	$130,000.00	N/A	N/A
Mangoceuticals	$866,792.00	5.68	-$9.21 million	($6.45)	-0.38

NewGenIvf Group has higher revenue and earnings than Mangoceuticals.

Risk and Volatility

NewGenIvf Group has a beta of 0.2, meaning that its stock price is 80% less volatile than the S&P 500. Comparatively, Mangoceuticals has a beta of 2.08, meaning that its stock price is 108% more volatile than the S&P 500.

Profitability

This table compares NewGenIvf Group and Mangoceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NewGenIvf Group	N/A	N/A	N/A
Mangoceuticals	-1,053.93%	-243.34%	-200.73%

Summary

NewGenIvf Group beats Mangoceuticals on 6 of the 9 factors compared between the two stocks.

About NewGenIvf Group

A SPAC I Acquisition Corp. is a blank check company. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or related business combination with one or more businesses. A SPAC I Acquisition Corp. is based in Singapore.

About Mangoceuticals

Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.